James is responsible for evaluating genetic targets and novel therapeutics as a part of the business development and new ventures efforts at RTW.
Prior to joining RTW, James was a Research Fellow at Memorial Sloan-Kettering Cancer Center, where he developed genome sequencing and bioinformatics platforms to study how gene regulatory elements control transcription during animal embryogenesis.
I am privileged to be part of such a talented, dedicated team at RTW, who are united around a common goal of translating scientific innovation into medicines that impact the lives of patients.
James has a PhD in Biochemistry and Molecular Biology from Weill Cornell Graduate School of Medical Sciences and a BS in Biology from Moravian College.